These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1589447)

  • 1. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
    Katzenschlager R; Weiss K; Rogatti W; Peskar BA; Sinzinger H
    Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of prostaglandin (PG) E1 and its initial metabolites on neutrophil-induced inhibition of human platelet aggregation.
    Pallapies D; Peskar BA
    Thromb Res; 1993 Aug; 71(3):217-25. PubMed ID: 8211888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between prostaglandin E1 and nitric oxide (NO).
    Katzenschlager R; Weiss K; Rogatti W; Stelzeneder M; Sinzinger H
    Thromb Res; 1991 May; 62(4):299-304. PubMed ID: 1866712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin E1 at clinically relevant concentrations inhibits aggregation of platelets under synergic interaction with endothelial cells.
    Koga T; Az-ma T; Yuge O
    Acta Anaesthesiol Scand; 2002 Sep; 46(8):987-93. PubMed ID: 12190800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
    Khanna V; Armstrong PC; Warner TD; Curzen N
    Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance.
    Sinzinger H; Neumann I; O'Grady J; Rogatti W; Peskar BA
    Prostaglandins Other Lipid Mediat; 1998 Apr; 55(5-6):265-75. PubMed ID: 9653766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
    Miyamori I; Morise T; Yasuhara S; Takeda Y; Koshida H; Takeda R
    Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A; Michael-Hepp J; Meyer J; Darius H
    Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-Keto-prostaglandin E1: its formation by platelets from prostacyclin and resistance to pulmonary degradation.
    Berry CN; Hoult JR
    Pharmacology; 1983; 26(6):324-30. PubMed ID: 6348806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
    Kikura M; Kazama T; Ikeda T; Sato S
    Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of platelet cyclic nucleotide content by PGE1 and the prostaglandin endoperoxide PGG2.
    Miller OV; Gorman RR
    J Cyclic Nucleotide Res; 1976; 2(2):79-87. PubMed ID: 177467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1.
    Bowen R; Haslam RJ
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):424-33. PubMed ID: 1711604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of TFC-612, a 7-THIA prostaglandin E1 derivative, on platelet function.
    Motoyama Y; Sakata Y; Seki J; Asada T; Namikawa Y; Horiai H; Ono T
    Thromb Res; 1991 Jun; 62(5):471-80. PubMed ID: 1654599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of TFC-612, a 7-thia prostaglandin E1 derivative, on platelet function.
    Motoyama Y; Sakata Y; Seki J; Asada T; Namikawa Y; Horiai H; Ono T
    Thromb Res; 1991 Jul; 63(1):29-38. PubMed ID: 1658963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.
    Chirkov YY; Chirkova LP; Sage RE; Horowitz JD
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):961-6. PubMed ID: 7564342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The binding of 6-oxo-prostaglandin E1 to platelet prostanoid receptors.
    Jaschonek K; Renn W; Weisenberger H
    Prostaglandins Leukot Med; 1986 Sep; 24(1):79-86. PubMed ID: 3020591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
    Weber AA; Reimann S; Schrör K
    Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental Differences in Platelet Inhibition Response to Prostaglandin E1.
    Palma-Barqueros V; Torregrosa JM; Caparrós-Pérez E; Mota-Pérez N; Bohdan N; Llanos MDC; Begonja AJ; Sola-Visner M; Vicente V; Teruel-Montoya R; Rivera J; Ferrer-Marín F
    Neonatology; 2020; 117(1):15-23. PubMed ID: 31786577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.